# Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

> **NCT06697366** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Irinotecan liposome injection Ⅱ
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06697366
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2026-05-20
- **Final completion:** 2026-11-20
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06697366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06697366, "Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06697366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*